Anzeige
Mehr »
Donnerstag, 23.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40MF2 | ISIN: US7574683014 | Ticker-Symbol: 2RH
NASDAQ
23.10.25 | 18:24
1,780 US-Dollar
+2,30 % +0,040
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REDHILL BIOPHARMA LTD ADR Chart 1 Jahr
5-Tage-Chart
REDHILL BIOPHARMA LTD ADR 5-Tage-Chart

Aktuelle News zur REDHILL BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiRedHill Biopharma to appeal Nasdaq compliance notice6
MiRedHill Biopharma Receives Nasdaq Staff Determination Notification46On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum...
► Artikel lesen
REDHILL BIOPHARMA Aktie jetzt für 0€ handeln
MoRedHill Biopharma Ltd. - 6-K, Report of foreign issuer-
MoRedHill Biopharma Ltd.: RedHill's Talicia Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal238Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S....
► Artikel lesen
06.10.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer4
29.09.RedHill Biopharma stock surges after court upholds $10M judgment27
05.09.RedHill Biopharma Ltd. H1 Earnings Summary21
05.09.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer15
05.09.RedHill Biopharma Ltd.: RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights184Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: ...
► Artikel lesen
14.08.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer8
21.07.Redhill Biopharma stock soars after FDA provides positive pathway for Crohn's drug40
21.07.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer7
21.07.RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease269The positive FDA feedback allows for: A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium...
► Artikel lesen
01.07.RedHill Biopharma Ltd.: RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer352Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...
► Artikel lesen
25.06.RedHill Biopharma Ltd. - F-1, Registration statement for certain foreign private issuers11
25.06.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer3
27.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer22
13.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer3
05.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer5
28.04.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer12
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3